Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lidan Xiaoshi Mixture is a traditional Chinese medicine (TCM) compound formulation used primarily for the prevention of recurrence of choledocholithiasis (common bile duct stones) after endoscopic retrograde cholangiopancreatography (ERCP). It is an herbal combination, typically administered as a liquid or granule, and is based on classical TCM principles aimed at promoting bile flow, dissolving gallstones, and supporting liver function. The mechanism of action involves multiple active herbal components that exert anti-inflammatory effects, regulate apoptosis pathways, and modulate oxidative stress responses. Key bioactive compounds identified in related formulations include quercetin, luteolin, and paeoniflorin. These act through multi-target interactions—most notably with interleukin-6 (IL6)—to reduce inflammation and prevent stone formation or recurrence[1][2]. The product is developed within the framework of Chinese medicine hospitals for use in hepatobiliary diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lidan xiaoshi mixture.